Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 219-863-1 | CAS number: 2554-06-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 10th September 2019 to 16th Dec 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 020
- Report date:
- 2020
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- June, 2018
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3700 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- August, 1998
- Deviations:
- not specified
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 2,4,6,8-tetramethyl-2,4,6,8-tetravinylcyclotetrasiloxane
- EC Number:
- 219-863-1
- EC Name:
- 2,4,6,8-tetramethyl-2,4,6,8-tetravinylcyclotetrasiloxane
- Cas Number:
- 2554-06-5
- Molecular formula:
- C12H24O4Si4
- IUPAC Name:
- 2,4,6,8-tetramethyl-2,4,6,8-tetravinyl-1,3,5,7,2,4,6,8-tetroxatetrasilocane
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- Crl:CD(SD)
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Inc., Raleigh, NC
- Age at study initiation: 10-12 weeks old
- Weight at study initiation: 200-250 g (Gestation day 0).
- Fasting period before study: not specified
- Housing: Animals were individually housed in clean, solid-bottom cages with appropriate bedding and equipped with an automatic watering valve.
- Diet: Certified Rodent LabDiet 5002 meal, ad libitum
- Water: tap water, ad libitum
- Acclimation period: 2-6 days.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 to 26 °C
- Humidity (%): 30 to 70%
- Air changes (per hr): ≥10 per hour
- Photoperiod (hrs dark / hrs light): 12 hours light /12 hours dark
- Other: 100 % fresh air with no air recirculation was maintained.
IN-LIFE DATES: not specified
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: Preparation occurred approximately weekly with an adequate amount of each formulation dispensed into daily aliquots. These aliquots were stored in a room with controls set to maintain a temperature between 18 to 24°C and protected from light until use.
VEHICLE
- Justification for use and choice of vehicle: the vehicle has been selected as suggested by the sponsor based on the test item's characteristics and testing guideline. The selected vehicle was corn oil.
- Concentration in vehicle: 0; 6.25; 25; 100 mg/mL
- Amount of vehicle: 4 mL/kg
- Lot/batch no.: 2IC0148, 1IG1538, and 2IH0387
- Purity: not specified - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Duplicate sets of samples (1.0 mL) for concentration analysis were collected twice during the study for all dose levels. Concentration results were considered acceptable if mean sample concentration results were within or equal to ± 15% of theoretical concentration.
Duplicate sets of samples (1.0 mL) for homogeneity analysis were collected once during the study from low dose and high dose groups. Homogeneity results were considered acceptable if the relative standard deviation of the mean concentration was ≤ 10% and if mean sample concentration results were within or equal to ± 15% of theoretical concentration.
Stability analysis was not performed since the test substance formulations have been previously shown to be stable over the range of concentrations used for this study for at least 8 days.
Analyses were performed by gas chromatography method using flame ionization detection using a validated analytical procedure. - Details on mating procedure:
- Time-mated females were received from Charles River Laboratories on gestation days 1, 2, 3 or 4.
- Duration of treatment / exposure:
- From gestation day 6 to 20.
- Frequency of treatment:
- Single daily dose
- Duration of test:
- From Gestation day 6 to 20.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Remarks:
- Control
- Dose / conc.:
- 25 mg/kg bw/day (nominal)
- Remarks:
- Low dose (LD)
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Remarks:
- Middle dose (MD)
- Dose / conc.:
- 400 mg/kg bw/day (nominal)
- Remarks:
- High dose (HD)
- No. of animals per sex per dose:
- 25 females per group.
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The dose selection was based on two previous dose range finding studies. The highest dose of 400 mg/kg bw/day was targeted to cause reduced body weight gains and feed consumption although not causing death or any obvious suffering. The lower doses were selected to provide dose response data for any observed toxicity and to establish a NOAEL value.
In a dose range-finding study, the test substance was administered to 5 male and 5 female (nonpregnant) Sprague Dawley rats per dose group via oral gavage for up to 14 consecutive days at dose levels of 0, 100, 300, 500, and 1000 mg/kg bw/day. All animals in the 1000 mg/kg bw/day group were euthanized in extremis on Day 8 following significant body weight losses in treated males during the first week of dosing. Mean body weights for the males was 15.9% lower and for females it was 5.2% lower than the concurrent control groups on Day 7. All other animals survived to the scheduled euthanasia. Test substance-related body weight losses or lower body weight gains, with corresponding lower food consumption, were generally noted for males and females in the 500 mg/kg bw/day group throughout the dosing period (Days 1–14), resulting in lower mean body weights than the control groups on Day 14. Lower body weight gains were also noted for males at 300 mg/kg bw/day and females at 100 and 300 mg/kg bw/day during Days 1–7, without corresponding lower food consumption or effects on mean body weights. Test substance-related increased liver weights (absolute and normalised) were noted in all test substance-treated males and females at the day 8/15 terminal necropsy. There were no correlations to differences in serum chemistry parameters.
In a dose range-finding prenatal developmental toxicity study, the test substance was administered to 5 pregnant Sprague Dawley females per dose group via oral gavage from Gestation Days 6–20 at dose levels of 0, 200, 400, and 600 mg/kg bw/day. 5 Females in the 400 and 600 mg/kg bw/day dose groups had decreased body weights gains (19% and 39%,respectively) and feed consumption (9% and 13%, respectively) over the Gestation Days 6–21 treatment period, which resulted in body weight decreases of 7% and 13%, respectively, on Gestation Day 21. All treated groups had increased absolute liver weights. A higher mean litter proportion of postimplantation loss (19.6% per litter) was noted in the 600 mg/kg bw/day group compared to the control group (3.2% per litter). A corresponding lower mean number of viable fetuses (8.5 per dam) was also observed in this group compared to the control group (12.6 per dam). The differences in this group were primarily attributed to 1 female, with 42.9% postimplantation loss and only 4 viable foetuses. Intrauterine survival was unaffected by test substance administration at dosage levels of 200 and 400 mg/kg bw/day.
- Rationale for animal assignment: randomised.
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Twice daily, in the morning and in the afternoon.
- Cage side observations checked included: The general health/mortality and moribundity was recorded.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: During the dosing period, observations were done once prior to dosing and once 1–2 hours postdose.
BODY WEIGHT: Yes
- Time schedule for examinations: on gestation day 0 and thereafter, daily during days 5-21.
FOOD CONSUMPTION AND COMPOUND INTAKE: Yes
- Food consumption was quantitatively measured on Gestation Days 5–21 (daily).
WATER CONSUMPTION AND COMPOUND INTAKE: No
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 21
- Organs examined: Animals were subjected to a complete necropsy examination, which included evaluation of the thoracic, abdominal, and pelvic cavities with their associated organs and tissues. The liver, thyroid gland and kidneys were weighed at necropsy for all scheduled euthanasia animals. Paired organs were weighed together. Tissues were collected from liver, kidneys, thyroid gland and all gross lesions. The thyroid gland from all females was embedded in paraffin, sectioned, mounted on glass slides, and stained with haematoxylin and eosin. The thyroid gland was examined microscopically from all females in all groups.
Thyroid hormones: Yes
- Blood samples for thyroid hormone analyses were collected (prior to noon in order to avoid diurnal fluctuations in thyroid hormone levels) via a jugular vein into tubes without anticoagulant on GD 21. The blood samples were analysed for triiodothyronine (total T3), thyroxine (total T4) and thyroid-stimulating hormone (TSH). - Ovaries and uterine content:
- The ovaries and uterine content were examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: the placentae were also examined. - Fetal examinations:
- - External examinations: Yes: all per litter
- Soft tissue examinations: Yes: approximately one half per litter
- Skeletal examinations: Yes: approximately one half per litter (those not used for soft tissue examinations)
- Head examinations: Yes: approximately one half per litter (those used in soft tissue examinations) - Statistics:
- All statistical tests were conducted at the 5% significance level. All pairwise comparisons were conducted using two sided tests and were reported at the 1% and 5% levels.
Numerical data collected on scheduled occasions for the listed variables were analysed as indicated by sex and occasion or by litter. Mean, standard deviation, percentage, and/or incidence were reported whenever possible. - Indices:
- No data
- Historical control data:
- yes, for the background incidence of fetal malformations and developmental variations (from Charles River Laboratories).
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No test substance-related clinical observations were noted at the daily examinations at any dosage level. Observations noted in the test substance-treated groups occurred infrequently, at similar frequencies in the control group, and/or in a manner that was not dose related. No clinical observations were noted 1-2 hours postdosing at any dosage level. With the exception of 1 female in the control group, all females were gravid.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Description (incidence):
- All females in the control, 25, 100, and 400 mg/kg bw/day groups survived to the scheduled necropsy on gestation days 21.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Mean maternal body weight losses were noted in the 400 mg/kg bw/day group following the initiation of dosing (gestation days 6–7 and 7–8), resulting in a statistically significant mean body weight loss in this group during gestation days 6–9. The only other statistically significant difference from the control group was a lower mean body weight gain in the 400 mg/kg bw/day group during gestation days 20–21. Although mean body weight gains in the 400 mg/kg/day group were generally comparable to the control during the remainder of the treatment period (gestation days 9–12, 12–15, and 15–21), the initial decrement resulted in a non-statistically significantly lower (11.4%) mean body weight gain in this group when the overall treatment period (gestation days 6–21) was evaluated.
Mean absolute body weights in the 400 mg/kg bw/day group were statistically significantly (6.1% and 5.7%) lower than the control group on gestation days 8 and 9. Thereafter, mean absolute body weight were generally comparable to the control group throughout the treatment period. However, mean corrected body weight and mean corrected body weight gain were statistically significantly (6.4% and 28.7%, respectively) lower in the 400 mg/kg bw/day group compared to the control group. The body weight effects in this group were considered test substance related and adverse.
Mean maternal body weights, body weight gains, corrected body weights, corrected body weight gains in the 25 and 100 mg/kg bw/day groups were unaffected by test article administration. Differences from the control group were slight and not statistically significant. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- In the 400 mg/kg bw/day dose group, lower mean food consumption (33.5% compared to control) was observed during gestation days 6-9. No other differences in the other dose groups occurred when compared to the control group.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Mean absolute liver weights in the 25, 100, and 400 mg/kg bw/day groups were statistically significantly higher (12.4% to 29.2%) than the control group. These effects were considered test substance related. A statistically significantly higher (9.6%) mean absolute kidneys weight was also noted in the 400 mg/kg bw/day group compared to the control group; this finding was not considered test substance related due to the magnitude of the change. No other statistically significant differences were noted at any dosage level.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- At the scheduled necropsy on gestation day 21, no test substance-related internal findings were observed at dosage levels of 25, 100, and 400 mg/kg bw/day. Macroscopic findings observed in the test substance-treated groups occurred infrequently, at similar frequencies in the control group, and/or in a manner that was not dose-related.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- There were no test substance-related histologic changes in the thyroid gland. All histologic changes were considered to be incidental findings or related to some aspect of experimental manipulation other than administration of the test substance. There was no test substance-related alteration in the prevalence, severity, or histologic character of those incidental tissue alterations.
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significantly lower mean T3 (44.4%) and T4 (38.5%) concentrations were noted in the 400 mg/kg bw/day group compared to the control group. In addition, statistically significantly higher (58.9% to 76.8%) mean TSH concentrations were noted in the 25, 100, and 400 mg/kg bw/day groups compared to the control group, albeit in a manner that was not clearly dose responsive and there was no corresponding test substance-related or dose-responsive change in mean T3 and T4 concentrations in the 25 and 100 mg/kg bw/day groups. These findings were considered test substance-related, but not adverse, due to lack of effects on the thyroid gland weight and histopathology.
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Changes in number of pregnant:
- no effects observed
- Other effects:
- no effects observed
- Description (incidence and severity):
- The mean numbers of corpora lutea was comparable to the control group.
- Details on maternal toxic effects:
- Intrauterine survival was unaffected by test substance administration at all dosage levels. Parameters evaluated included postimplantation loss, live litter size, and foetal sex ratios. Mean numbers of corpora lutea and implantation sites and the mean litter proportions of pre-implantation loss were similar across all groups.
Effect levels (maternal animals)
- Dose descriptor:
- NOAEL
- Effect level:
- 100 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
Maternal abnormalities
- Abnormalities:
- effects observed, treatment-related
- Localisation:
- other: Body weight
- Description (incidence and severity):
- Decreased body weight at 400 mg/kg bw/day
Results (fetuses)
- Fetal body weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Mean foetal body weights (male, female, and combined sexes) in the 400 mg/kg bw/day group were statistically significantly lower (14.9% to 16.2%) than the concurrent control group. The values were also below the respective minimum mean values in the Charles River Ashland developmental historical control data (version 2019.01). Therefore, the lower mean foetal body weights in this group were considered test substance-related and adverse. Mean foetal body weights in the 25 and 100 mg/kg bw/day groups were unaffected by test substance administration.
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- no effects observed
- External malformations:
- no effects observed
- Description (incidence and severity):
- No test substance-related external malformations were observed in foetuses in this study. One foetus in the 100 mg/kg bw/day group had a small left eye bulge and one foetus in the 25 mg/kg bw/day group had a cleft palate (entire length). In the absence of a dose response, these malformations were not considered test substance-related.
No external developmental variations were observed in foetuses in this study. - Skeletal malformations:
- effects observed, treatment-related
- Description (incidence and severity):
- No test substance-related foetal malformations were observed at any dosage levels.
In the 25 mg/kg bw/day, one female was observed with split palatine plates, corresponding to cleft palate noted externally. However, this was considered as not test-item related in the absence of a dose response occurring.
At 400 mg/kg bw/day, test substance-related skeletal developmental variations were noted. They included the findings of delayed ossification which correspond to the lower foetal weights in the same group and were considered nonadverse as they were expected to resolve over time. - Visceral malformations:
- no effects observed
- Description (incidence and severity):
- No test substance-related visceral malformations were observed in foetuses in this study. One foetus in the 400 mg/kg bw/day group had a retroesophageal right subclavian artery; however, this was noted for a single foetus, the mean litter proportion was not statistically significant compared to the control group, and the value was within the Charles River Ashland developmental historical control data range. Therefore, this malformation was not considered test substance-related. No test substance-related visceral developmental variations were observed in foetuses in the study. Findings observed in the test substance-treated groups were noted infrequently, similarly in the control group, were not observed in a dose related manner, the differences in the mean litter proportions were not statistically significant compared to the concurrent control group, and/or the values were within the ranges of the Charles River Ashland developmental historical control data.
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- A statistically significant shorter mean absolute anogenital distance (11.3%) was noted in the 400 mg/kg bw/day group males compared to the control group; however, mean anogenital distance relative to the cube root of the body weight in these males was only 6.3% lower than the control group and not statistically significant. Because the mean anogenital distance in this group was only slightly shorter than noted in the control group and was not statistically significant when normalized to body weight, the difference in mean absolute anogenital distance in the 400 mg/kg bw/day group males was considered secondary to the lower mean foetal body weights. Mean absolute and relative anogenital distances for female foetuses in this group were comparable to the control group. Mean anogenital distances in the 25 and 100 mg/kg bw/day groups were comparable to the control group.
Effect levels (fetuses)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 100 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- fetal/pup body weight changes
- Remarks on result:
- other: test item-related and adverse findings at 400 mg/kg bw/day
Fetal abnormalities
- Key result
- Abnormalities:
- effects observed, treatment-related
- Description (incidence and severity):
- see foetal NOAEL above
Overall developmental toxicity
- Key result
- Developmental effects observed:
- yes
- Lowest effective dose / conc.:
- 400 mg/kg bw/day
- Treatment related:
- yes
- Relation to maternal toxicity:
- not specified
- Dose response relationship:
- yes
- Relevant for humans:
- yes
Any other information on results incl. tables
Relation to maternal toxicity: Uncertain at this time if the developmental effects are a secondary non-specific consequence of maternal toxicity effects.
Applicant's summary and conclusion
- Conclusions:
- In an oral prenatal developmental toxicity study, conducted according to OECD Test Guideline 414 and in compliance with GLP, a maternal and prenatal development NOAEL was determined to be 100 mg/kg bw/day based on lower maternal and foetal body weights at 400 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
